ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) shares shot up 4.6% during trading on Monday . The company traded as high as $17.41 and last traded at $17.27. 244,025 shares were traded during mid-day trading, a decline of 84% from the average session volume of 1,543,815 shares. The stock had previously closed at $16.52.
Analyst Ratings Changes
Separately, Wall Street Zen upgraded ARS Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, June 28th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, ARS Pharmaceuticals has an average rating of "Buy" and an average price target of $31.00.
Get Our Latest Research Report on SPRY
ARS Pharmaceuticals Price Performance
The company has a debt-to-equity ratio of 0.30, a quick ratio of 10.74 and a current ratio of 11.00. The firm has a market capitalization of $1.68 billion, a P/E ratio of -106.81 and a beta of 0.90. The company has a 50-day moving average price of $14.91 and a 200-day moving average price of $13.25.
ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, hitting the consensus estimate of ($0.35). The business had revenue of $7.97 million for the quarter, compared to the consensus estimate of $7.48 million. ARS Pharmaceuticals had a negative return on equity of 6.94% and a negative net margin of 16.11%. On average, sell-side analysts predict that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.
Insider Buying and Selling at ARS Pharmaceuticals
In other ARS Pharmaceuticals news, insider Eric Karas sold 15,000 shares of ARS Pharmaceuticals stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $16.99, for a total value of $254,850.00. Following the sale, the insider owned 10,315 shares of the company's stock, valued at $175,251.85. This trade represents a 59.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Brent L. Saunders sold 120,000 shares of ARS Pharmaceuticals stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $14.25, for a total value of $1,710,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 1,043,118 shares of company stock worth $18,024,863 in the last three months. 33.50% of the stock is owned by insiders.
Hedge Funds Weigh In On ARS Pharmaceuticals
A number of institutional investors have recently bought and sold shares of SPRY. Steward Partners Investment Advisory LLC lifted its stake in ARS Pharmaceuticals by 47.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 38,050 shares of the company's stock worth $401,000 after purchasing an additional 12,200 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of ARS Pharmaceuticals by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 427,477 shares of the company's stock valued at $4,510,000 after buying an additional 3,530 shares during the period. Aigen Investment Management LP acquired a new stake in shares of ARS Pharmaceuticals in the 4th quarter valued at about $216,000. Raymond James Financial Inc. acquired a new position in ARS Pharmaceuticals during the 4th quarter valued at about $6,576,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in ARS Pharmaceuticals by 4.4% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 80,641 shares of the company's stock valued at $851,000 after purchasing an additional 3,433 shares during the last quarter. Institutional investors and hedge funds own 68.16% of the company's stock.
About ARS Pharmaceuticals
(
Get Free Report)
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
Recommended Stories
Before you consider ARS Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ARS Pharmaceuticals wasn't on the list.
While ARS Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
